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Background: Due to an increased risk of sexually transmitted infections (STIs), gay, 
bisexual and other men who have sex with men (MSM) have been recommended to receive 
vaccinations against human papillomavirus, meningitis C and hepatitis A/B. This review 
aimed to compare the rates of vaccine acceptability, uptake and completion, and to identify 
determinants of vaccine outcomes specific to MSM to inform a theoretical framework. 
Methods: In January 2020 four databases were explored to identify vaccination behaviours 
and associated factors among MSM. A narrative systematic review and meta-analysis were 
performed. Data were synthesised for theoretical modelling. Results: Seventy-eight studies, 
mostly from the USA, were included. The average vaccine acceptability was 63% 
(median=72%, range: 30%-97%), vaccine uptake 45% (median=42%, range: 5%-100%) and 
vaccine completion 47% (median=45%, range: 12%-89%). Six categories of factors 
associated with vaccination acceptability, uptake and completion were conceptualised: 
Individual (e.g., demographic and psychosocial); Interpersonal (e.g., peer education); 
Healthcare provider (e.g., vaccine recommendation); Organisational and practice setting (e.g., 
routine collection of patient sexual orientation information that is integrated into a clinical 
decision support system); Community environment (e.g., targeted health promotion 
campaigns); and National, state and local policy environment (e.g., public health guidelines 
targeting MSM). Conclusion: Despite overall high levels of acceptability, uptake and 
completion rates were below targets predicted by cost-effectiveness modelling across all 
recommended vaccines. These parameters may need to be adjusted for more precise 
estimations of cost-effectiveness. Addressing the multiple levels of determinants, as outlined 
in our theoretical framework, will help guide interventions to increase vaccine completion 
among MSM. 
Keywords: Gay, Bisexual, MSM, HPV, Meningitis, HAV, HBV, vaccination
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INTRODUCTION
Gay, bisexual and other men who have sex with men (MSM) are at an increased risk 
of sexually transmitted infections (STIs) associated with substantial physical and mental ill-
health.[1-2] Marginalisation, stigmatisation, homophobia and social attitudes towards 
homosexuality have had a negative impact on access to healthcare and preventative 
treatments for MSM, contributing to health disparities due to sexual orientation.[3] The MSM 
population globally is estimated to be between 0.3% to 6.5%, but MSM carry a substantial 
burden of all STIs.[4] There is evidence of syndemicity, where mental health issues, 
substance abuse, and/or the experience of violence co-occur with higher rates of STIs.[5] 
Specific psycho-social factors also influence the susceptibility to STIs, such as the lack of 
disclosure of same-sex sexual practices to health professionals (HCPs) resulting in reduced 
access to relevant healthcare services, notably screening and vaccinations.[6] 
The MSM community are at greater risk of hepatitis A (HAV) and B (HBV) viruses, 
human papillomavirus (HPV) and meningitis C (MenC); infections that are all preventable 
with effective vaccinations. Although gender-neutral and universal vaccination programmes 
in childhood are the most effective strategies against communicable diseases, many countries, 
including Australia, Brazil, Canada, Germany, Ireland, Mexico, the Netherlands, Thailand, 
Taiwan, UK and USA, have at some point adopted a selective approach to vaccination 
targeting only high-risk individuals, including MSM. This approach is guided by cost-
effectiveness modelling comparing the speculated financial benefits of selective vaccination 
programmes over universal immunisation, when the benefits of the universal approach are 
expected to be marginal. Predicted vaccination uptake rates inform cost-effectiveness 
modelling, with some using the above 80% uptake as a parameter for the estimation.[7] Thus, 
uptake rates below the 80% mark would be deemed as suboptimal and less cost-effective. 
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 In the past 30 years, vaccination programmes targeting MSMs’ higher risk of HPV, 
HAV, HBV or MenC have been included in the national guidelines of many countries. 
Unfortunately, selective vaccination policies have not realised any benefit for MSM, but 
rather maintained the gap in sexual health inequity between MSM and men who have sex 
with women (MSW). For example, the UK NHS vaccination programme in 2008 offered the 
HPV vaccination to all girls aged twelve to thirteen to protect against HPV-induced cervical 
cancer. This female-only strategy achieved ‘herd protection’ for young women and 
unvaccinated men of corresponding age. There was a dramatic decline in HPV amongst 
young unvaccinated heterosexual men, but the rates of HPV infection in MSM remained 
stable, illustrating how a selective strategy can widen health inequalities.[8] Taking this into 
account, along with additional evidence that HPV is associated with genital warts and non-
cervical cancers, an MSM-selective HPV vaccination program was piloted in England from 
2016 for gay and bisexual men aged up to 45 years attending sexual health clinics. However, 
only half of MSM initiated the vaccine within the first 12 months [9], indicating a need for 
parallel public health investments, community engagement and individual-level behaviour 
change interventions to improve awareness and vaccine initiation among MSM. In 2018, the 
economic modelling was revised taking into account the costs of HPV-related cancers, such 
as oral cancers in heterosexual men.[9] As a result, since 2019 all adolescent boys have been 
offered HPV vaccine, regardless of their sexual orientation. 
In the future selective vaccination programmes may be considered for other diseases 
impacting the MSM community; these include the potential HIV vaccination and the 
partially-effective meningitis B vaccination against gonorrhoea [10-11]. If selective 
vaccination strategies are used, it is essential to understand how these should be developed to 
achieve the best possible uptake and clinical outcomes. Understanding barriers and 
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facilitators to vaccinate initiation in MSM would help inform the development of effective 
public health interventions and modelling studies on which vaccination policies are based.  
Vaccine acceptability and behaviour
Vaccine acceptability (or ‘acceptance’) is a heterogeneous construct referring to the 
degree to which an individual is willing to undergo the recommended course of vaccination. 
The concept of acceptability has been focused on understanding the demand for vaccination 
and resultant adherence. Active demand represents intentional seeking of vaccination by an 
informed individual who perceives benefits and need of a particular vaccination. In contrast, 
passive acceptability reflects compliance with recommendations from healthcare 
professionals and community leaders in line with recommended public health programmes. 
Although acceptability of health interventions has been conceptualised [12], there is no single 
construct of ‘vaccine acceptability’ and historically it has been most commonly 
operationalised as ‘agreement’, ‘ acceptance’, ‘willingness’, ‘perceived likelihood’ or 
‘intention’ to be vaccinated.[13] Other terms such as ‘vaccine hesitancy’ have been used as 
an indicator of delay, deferral or vaccination refusal and observed as a continuum between 
vaccination receipt and rejection.[14] In general, acceptability is closely related to motivation 
and decision-making processes and studies of acceptability aim to identify individuals that 
have negative attitudes towards vaccines, resulting in a lack of vaccination adherence. 
Previous reviews examining vaccination behaviours in MSM have focussed on existing 
vaccines, notably HPV [15], HBV [16-17] and the hypothetical acceptability of a vaccine for 
HIV [11], indicating moderate-to-high levels of acceptability.  
Vaccine uptake and completion describe actual vaccine behaviours and go beyond 
motivation. The term ‘uptake’ refers to the initiation or administration of the first vaccination 
dose, but sometimes multiple doses are needed within a given time to achieve sufficient 
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immunological response. Thus, incomplete vaccination compromises effectiveness, making 
vaccine completion the most important indicator of the success of a vaccination regimen. 
To date, no review has synthesised data on vaccination acceptability and behaviour 
(i.e. uptake and completion) among MSM. Furthermore, there has been no systematic 
synthesis of the correlates of acceptability and behaviour related to vaccinations against STIs 
in MSM. To inform the development of vaccination programmes for future vaccine-
preventable STIs in MSM this review aimed: i) to estimate the pooled rates of vaccine 
acceptability, uptake and completion in MSM; and ii) to identify the positive and negative 
correlates of vaccine behaviours in MSM. 
METHODS
This systematic review followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.[18] 
Search strategy
Pubmed, Web of Science, Embase and Scopus were explored to identify relevant 
articles published before 30st of January 2020 (Figure 1). There were no time or geographical 
restrictions for the published articles. Specific MeSH terms were individually adjusted to 
each database using the following words: (human papillomavirus, HPV) or (hepatitis, HAV, 
HBV) or (meningitis, meningococcal) and (vaccin*, immuni*, jab, inoculat*) and (gay, 
MSM, homosexual*, bisexual*).
Eligibility
The specific inclusion for study selection were: 
i) Peer-reviewed original studies written in English. Editorials, reviews, modelling 
analyses and conference proceedings were excluded. 
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ii) Studies on vaccination acceptability, uptake and completion for preventative 
vaccines against HPV, HAV, HBV and MenC. Hypothetical vaccines, such as 
HIV or hepatitis C, or those not specifically aimed at MSM (e.g. ‘flu vaccine) 
were excluded. Articles reporting vaccine knowledge or similar cognitions 
without detailing vaccination behaviours or correlates were excluded. 
iii) Studies about gay, bisexual and other men who have sex with men (MSM) of 
various sexual and gender identities, including cis men as well as transgender men 
and women. Studies not focussing entirely on MSM population and reporting 
insufficient cases (<5% or <50 cases) to draw meaningful conclusions were 
excluded.
iv) Quantitative or mixed-methods studies. Purely qualitative studies were excluded.  
Selection process 
Database searches were conducted by three reviewers (TN, MF, DM). Records from 
each database were transferred to EndNote, a bibliographical management tool, to remove all 
duplicates. The articles were screened for relevance against the inclusion/exclusion criteria, 
first reviewing titles and abstracts, and then the full-text articles for all those appearing to 
meet the eligibility criteria. The reviewers worked independently and then achieved 
consensus in group discussion. The reviewers also hand-searched the reference sections of 
relevant systematic reviews and articles meeting the inclusion criteria for additional studies. 
If a study reported on male vaccination in general, but with a substantial proportion of MSM, 
the authors were asked clarification about the MSM-specific data if necessary. Key authors of 
relevant articles were also contacted to identify additional publications for inclusion. 
Data extraction, synthesis and meta-analysis
The data extracted included authors, publication year, country, number of MSM 
participants, vaccine type, study design, sample characteristics, the rates of vaccine 
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acceptability, uptake and completion as well as their statistically significant correlates, both 
positive and negative. The data was collated in a spreadsheet; data from multiple publications 
but relating to one study were merged to avoid bias. Data synthesis was undertaken to create 
a narrative outline comparing rates of vaccine acceptability, initiation and completion across 
the four vaccine types and explored the similarities and differences in identified correlates. 
The data synthesis informed the construction of a theoretical framework by TN and 
CW to explain and predict MSM’s vaccination behaviours. A mapping exercise was used to 
construct a basic model of barriers and facilitators for vaccinations in MSM. This 
subsequently informed charting of demographic, behavioural and psychological factors that 
were then grouped thematically to construct levels of various influences on vaccine 
acceptability and behaviours, such as individual and community-level factors. The mapping 
of identified correlates used a socio-ecological approach [19] to organise them into distinct 
levels of influence on individual behaviour. The face validity of the framework was 
confirmed in discussions with co-authors. 
Multilevel mixed-effects meta-regression models (Supplementary file A) were 
estimated to account for effect size dependency, using log-odds as the outcome measures, 
with random slopes for each dependent variable (acceptability, uptake, completion) nested 
within studies. A compound symmetric structure for the random effects was used, estimating 
a single random effects variance and correlation for all three dependent variables. The 
amount of heterogeneity (i.e., ) was estimated using the restricted maximum-likelihood τ
estimator. Cook’s distances were used to examine whether studies were overly influential in 
the context of the model. Studies with a Cook’s distance larger than the median plus six times 
the interquartile range of the Cook’s distances were considered to be overly influential. 
Confidence intervals and prediction intervals were computed using the Knapp and Hartung -t
distribution method. Models were estimated using R and the metafor packages. 
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Quality and relevance assessment
Appraisal Tool for Cross-Sectional Studies (AXIS tool) was used to assess the overall 
quality and risk of bias in cross-sectional studies.[20] The AXIS tool does not generate a 
global quality assessment score but rather evaluates individual characteristics. In this review, 
AXIS enabled the identification of methodologically weaker studies and those with higher 
and lower relevance for an MSM-selective vaccination programme. Thus, studies were 
categorised to be of either ‘higher’, ‘medium’ or ‘lower’ quality and relevance. 
RESULTS
Search results & quality assessment
In total, 3706 records were identified through database searches, 1143 titles and 
abstracts were screened after removing duplicates, and 327 papers reviewed in full. Seventy-
eight studies were included in this review (Table 1). 
The methodological quality of the studies and their relevance for an MSM-selective 
vaccination approach varied: Lower (9), Medium (32) and Higher (37). Most studies of 
medium or lower quality had either not justified their sample size, stated their response rate, 
funding source or commented on conflicts of interest. 
Study characteristics
Vaccination acceptability and behaviours were explored for HPV (33 studies), HBV 
(24), HBV &  HAV (9), HAV (5), MenC (4) and HPV & HBV & HAV (3). Studies were 
published from 1990 to 2020 and originated from USA (43), Netherlands (7), United 
Kingdom (7), Australia (6), Canada (3), China (3), Taiwan (2). Hong Kong (1), Italy (1), 
Germany (1), Mexico (1), Ireland (1), Brazil (1) and Thailand (1). Studies were 
predominantly cross-sectional with 64 studies, 5 service evaluation, 9 cohort studies and 3 
experimental. Convenience sampling was the most common recruitment strategy within the 
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following locations: healthcare settings, e.g. sexual health clinics (24), internet-based panels 
and online LGBT networks (20), LGBT community settings such as pride events, gay bars 
and gyms (16), large clinical datasets (9), university/college settings (1) and a combination of 
various community and healthcare settings (7). Nineteen studies were grounded in theoretical 
frameworks: Health Belief Model (12), Theory of Planned Behaviour (8), Social Cognition 
Theory (3), Diffusion of Innovation (1), Model of Persuasion (1), Syndemic Conceptual 
Theory (1), Protection Motivation Theory (1), Reasoned Action Approach (1), and 
Integrative Model of Behavioural Prediction (1). 
This review reports on vaccine acceptability and behaviours among 134,038 MSM. 
The synthesis reflects studies of mostly men of white ethnicity, university educated with 
access to healthcare. While most of the HPV vaccination studies focussed on younger MSM 
(<26 years), the studies of HBV, HAV and MenC vaccinations surveyed men in their 30s. 
Vaccine acceptability
Studies predominantly focussed on HPV vaccine acceptability (18), with fewer 
examining HBV (3) or combined HBV&HAV (1). Across all studies, the average vaccine 
acceptability was 63% (median=72%, range: 30%-97%) in MSM, or if reported on Likert-
type scales acceptability was within the third and fourth quartiles. The lowest acceptability 
(30%) was reported in an Australian study of 16-20 years old MSM who were asked about 
the hypothetical purchasing of the HPV vaccine for $450.[22] In contrast, the highest 
acceptability of 97% was reported among MSM in China recruited through a non-
governmental organization and an outpatient HIV clinic.[48] In this study, acceptability of a 
free HPV vaccine was even higher in MSM living with HIV (99%), decreasing to 80% 
should payment be needed. Free vaccination yielded higher acceptability and direct payment 
lower acceptability in four other studies.[26,31,39,48] There was an upward trend in HPV 
vaccine acceptability over time, reflecting changes in policies and guidelines recommending 
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MSM-selective vaccination programmes. In general, higher rates of acceptability were found 
amongst MSM attending sexual health clinics compared to those in the community. 
Fifty-eight distinct correlates of vaccine acceptability (39 positive and 18 negative) 
were identified (Table 2). Within demographic correlates, older MSM, those who identified 
as an ethnic minority within predominantly White populations, as well as those who lived in 
less urbanised areas reported lower vaccine acceptability. MSM in full-time employment, had 
higher educational levels or household incomes, were more likely to accept vaccination. Men 
who disclosed their sexual orientation to an HCP, accessed sexual health services, notably 
STI/HIV screening or had received vaccines in the past reported higher vaccine acceptability. 
Personal risk indicators associated with greater vaccination acceptability were MSM who 
identified as ‘homosexual/gay’, had a greater number of sexual partners, had been diagnosed 
with an STI/HIV or engaged in anal intercourse. Conversely, MSM who had never visited an 
LGBT-community venue nor used any gay dating apps to meet other men reported lower 
acceptability. Awareness and knowledge about viral infections and the preventative vaccines, 
as well as being exposed to promotional material about vaccinations, were associated with 
higher acceptability. Several psychological variables, including higher perceived severity and 
susceptibility of infection, concerns, worry and anxiety about virus-induced diseases were 
associated with higher acceptability. Positive attitudes and perceptions of the vaccines 
concerning the benefits, effectiveness and their protective properties as well as higher self-
efficacy, perceived behavioural control, social norms and anticipated regret correlated with 
higher acceptability. Lower vaccine acceptability was associated with higher perceived 
practical and clinical barriers such as vaccine cost, side effects, lack of time and a fear of 
needles. Stigma, embarrassment and the belief that vaccination was a sign of promiscuity or 
that it was aimed at women only, correlated with lower acceptability. 
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Vaccine uptake
Studies of vaccine initiation or uptake of a single dose of a vaccine predominantly 
focussed on those against HBV (17), HPV (17), HAV (5) and MenC (4), or a combination or 
HBV, HAV and HPV vaccines (11). The average vaccine uptake in MSM across all studies 
was 45% (median=42%, range: 5%-100%). For HPV vaccine it was 37% (median=26%, 
range: 5%-100%). The average uptake for HBV and HAV vaccines was 50% (median=49%, 
range: 9%-88%) and 49% (median=53%, range: 17%-89%), respectively. The average uptake 
for the MenC vaccination was 42% (median=38%, range: 23%-67%). The lowest reported 
rate of vaccine uptake of 5% was reported in 2011 for HPV vaccination of younger MSM 
(18-26 years old) across 20 USA cities, 1 year after the MSM-selective recommendation by 
the U.S. Center for Disease Control and Prevention.[27] Subsequent cohort analyses 
demonstrated an increase in HPV vaccine to 41% by 2014 within those geographical 
locations.[40] One hundred percent vaccine uptake was reported in Rhode Island (USA) 
where the vaccination program was accompanied by a package of MSM-relevant healthcare 
services including specialist risk assessment, HIV testing, behavioural risk reduction 
counselling and a $20 incentive for each visit.[28]
There was an association between time since vaccine availability and uptake rates 
(Figure 2). In 2015, the average uptake of HPV vaccine was only 32%, with a large amount 
of heterogeneity across studies [95% prediction interval (PI) 5%, 81%]. Uptake was 
estimated to be higher for Hepatitis A (2015 mean = 69% [95% PI 19%, 95%]) and Hepatitis 
B  vaccinations (2015 mean = 74% [95% PI 23%, 96%]), but still heterogeneous. Few studies 
reported results for Meningitis C , but uptake rates appeared to be similar to HPV 
vaccination, (2015 mean = 40% [95% PI 5%, 89%]). Based primarily on data from the 
longer-established Hepatitis B vaccine, uptake rates appeared to increase over time (e.g, HBV 
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2000 mean = 46% [95% PI 8%, 89%], HBV 2008 mean = 62% [95% PI 15%, 94%], HBV 
2015 mean = 74% [95% PI 23%, 96%]). 
Seventy-five distinct correlates of vaccine uptake (60 positive and 15 negative) were 
identified. Amongst demographic correlates, age was highly correlated with uptake in a 
curvilinear fashion; MSM below the age of 25 years or above the age of 40 were less likely to 
initiate vaccinations. Similar to vaccine acceptability, studies of vaccine uptake reported 
positive associations with higher level of education, income and employment, living in urban 
areas and being from a White ethnic background. Healthcare utilisation, such as frequent STI 
screening, disclosure to HCP of sexual orientation, receipt of HCPs’ recommendations to 
vaccinate, previous vaccinations, using PrEP or receiving HIV care, were all positively 
correlated with uptake. Behavioural indicators of higher risk of getting an STI such as the 
number of sexual partners, previous STI diagnosis, HIV positive status, engaging in 
unprotected anal intercourse, having sex in bathhouses and using recreational drugs were 
correlated with uptake. Several indicators of lower STI risk were positively correlated with 
uptake, such as being in a relationship, taking daily multivitamins or receiving travel-related 
vaccinations. Awareness and knowledge about the virus and vaccinations as well as accessing 
information about available vaccines (e.g. local gay newspapers or peer education) or 
counselling from an HCP were associated with uptake. Perceived risk of infection, 
vaccination effectiveness and benefits, self-efficacy, social norms, motivation, positive 
attitudes and implementing intentions positively correlated with uptake. Perceptions of 
multiple barriers to vaccination and concern about sexual orientation disclosure were 
negatively associated with uptake. 
Vaccine completion
Studies of vaccine completion, of two or three doses as per guidelines, mainly 
focussed on those against HBV (10),  HPV (9), MenC (1) or a combination of HBV, HAV 
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and HPV (3) vaccines.  The average vaccine completion across all studies was 47% 
(median=45%, range: 12%-89%). The average completion for HBV vaccine was 57% 
(median=59%), HPV (average=28%, median=40%), HAV (27% and 28% in two studies) and 
50% for MenC in HIV-positive MSM. The lowest vaccine completion (12%) was reported in 
Scotland after one year of an MSM HPV immunisation programme provided by sexual health 
services.[54] In contrast, the highest vaccine completion rate of 89% was achieved in 
Thailand among MSM recruited through the internet and community-based outreach 
programmes.[76] 
Twenty-eight distinct correlates of vaccine completion (23 positive and 5 negative) 
were identified. Vaccine completion was positively correlated with the demographic 
characteristics of older age, higher income, higher education level, employment and living in 
an urban area. Generally, the regural utilisation of sexual health services and being reminded 
to complete vaccination directly by an HCP or through text messages were associated with 
completion. As seen with vaccine acceptability and uptake, men of higher risk of acquiring an 
STI (i.e. higher number of sexual partners, previous STI diagnosis, HIV positive status, 
exclusively homosexual identity, alcohol use before/during sex) were more likely to complete 
the vaccination course. Being in a stable relationship or travelling to a hepatitis-endemic 
country also correlated with completion. One study reported that exchanging goods, money 
or drugs for sex were negatively associated with vaccination completion. While the perceived 
severity of infection, self-efficacy and perceived benefits of vaccination were positively 
associated with completion, perceived personal barriers correlated negatively.  
Moderators of vaccine behaviours (meta-analysis)
The effects of moderator variables (i.e. vaccine type, year of data collection, 
recruitment setting, sampling method, participant age, sexuality, ethnicity, education, HIV 
status and health insurance) were generally small, and in most cases, confidence intervals 
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overlapped substantially, even for moderator values at opposite extremes (e.g., estimated 
values for samples with 0% and 100% higher education) (Supplementary File A). Some 
moderators appeared to have substantial effects (e.g., population-based samples showed 
lower rates than convenience samples; those with higher HIV prevalence showed higher 
rates), but wide confidence intervals preclude definitive conclusions. An exception to this 
pattern was that rates were higher outside the US (e.g., for 2015 HPV uptake, US mean = 
24% [95% PI 5%, 65%], non-US mean = 46% [95% PI 7%, 90%]). Similarly, samples 
recruited in healthcare settings showed higher uptake rates than other recruitment approaches. 
Unexpectedly, rates were estimated to be lower when the sample had greater access to 
healthcare/health insurance (e.g., for 2015 HPV uptake, mean at 50% insured = 25% [95% PI 
8%, 56%], mean at 100% insured = 9% [95% PI 2%, 27%]).
DISCUSSION
This review synthesises the literature on acceptability, uptake and completion of each 
of four different vaccines with current recommendations specific to MSM. Our findings 
demonstrate generally positive views on vaccinations against STIs with over half of MSM 
motivated to undergo vaccination. However, the multiple barriers faced by MSM appear to 
generate an ‘intention-behaviour gap’, with over a quarter of MSM not initiating vaccination, 
and approximately half of those who receive the first dose not completing the recommended 
course. This review indicates that vaccination programmes aimed at MSM may achieve high 
levels of vaccine acceptability, but uptake and completion may not reach levels as predicted 
in cost-effectiveness modelling.[7] As such, to improve vaccination rates in MSM to an 
adequate level may require additional support and investment for public health programmes 
as well as a consideration of universal vaccination approaches. 
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The analysis identified nearly 100 distinct correlates of vaccination acceptability and 
behaviour in MSM. There was a substantial overlap of associated factors across vaccine 
acceptability, uptake and completion, suggesting a specific set of determinants that represent 
components from across social cognition models. At the individual level, studies have shown 
that younger or much older MSM, from lower socio-economic backgrounds, with less 
education and lower social mobility, are less likely to accept, initiate, and complete 
vaccinations (see Table 2 for demographic factors). There are also significant differences by 
race and ethnicity, with minority subgroups exhibiting lower acceptability and uptake of 
vaccines. Attitudes and beliefs about perceived low susceptibility and severity of infection, 
perceived lower vaccine effectiveness or limited benefits are associated with suboptimal 
uptake and completion. MSM who perceived multiple barriers were less likely to engage with 
vaccination services and studies consistently outlined that personal financial cost of 
vaccination decreased acceptability. MSM-selective vaccination approaches are unlikely to 
reach ‘seldom heard’ or hard-to-reach MSM outside of large urban areas with limited access 
to MSM-specific healthcare services.[42-44,48,59,69,70,73]    
At the interpersonal level, perceived norms were positively associated with vaccine 
acceptability and uptake, however, the influence of family and peers in vaccine decisions 
appears less important among MSM than in other vaccine eligible populations (e.g. 
adolescents, young adult women).[105-106] Identifying the most influential or credible 
referent group for MSM is critical; the peer influencers or other popular opinion leaders may 
vary depending on the level of connectedness to the LGBT community.[107-108]
Individual and interpersonal factors interrelate with restricted access and utilisation of 
healthcare, notably specialist sexual health and vaccination services for MSM and other 
sexual minorities. Men with restricted access to sexual networks and LGBT community 
resources, those living in less urbanised geographical locations, of a lower behavioural risk 
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profile, who do not identify as ‘gay’ or are unable to disclose their same-sex sexual practices 
to HCPs may be less motivated to initiate and complete vaccination. Expecting stigmatisation 
and discrimination in healthcare environments deters vaccination uptake among MSM, 
especially for vaccinations against STIs.[30, 109] Therefore, the opportunity to disclose 
sexual orientation or same-sex sexual practices to healthcare providers that are sensitive and 
receptive to MSMs’ needs is essential to the success of selective vaccination programmes. 
These findings highlight the importance of intervening at a structural level (e.g. among 
healthcare providers, organisations serving MSM) as well as with individuals, to facilitate 
activities within and across communities such as vaccination outreach or peer 
education.[30,109] Unlike heterosexual men, younger MSM face multiples barriers related to 
the formation of sexual identity, hence support and education around working with sexual 
and gender minority groups is essential.  
Our findings are consistent with the three previous reviews on HPV and HBV 
vaccinations and the utilisation of sexual health services in MSM [12-14] demonstrating 
barriers to acceptability and uptake. However, the present review offers a more 
comprehensive outline of the vaccination behaviour spectrum from acceptability to 
completion. A meta-analysis of 29 studies on HPV vaccine acceptability in men, regardless 
of their sexual orientation, reported that only a half were motivated to receive it, similar to the 
rate identified in the present review.[109] It showed that receiving an HCP recommendation 
to vaccinate as well as perceptions of vaccine benefits and barriers were associated with 
acceptability. Another systematic review of HPV vaccine acceptability in women 
demonstrated similar findings, highlighting the role of healthcare professionals in promoting 
vaccination and influencing perceptions, beliefs and attitudes towards the vaccine.[110] Also, 
previous reviews identified similar barriers to HIV testing in MSM [111-113], indicating that 
demographic characteristics such as age, ethnicity, sexual identity, education, income as well 
18
as perceived stigma, poor healthcare utilisation and the lack of active encouragement from 
healthcare professionals were associated with screening uptake. A meta-analysis of 29 studies 
on a hypothetical HIV vaccine acceptability also reported that over a half of participants 
(65%) would be willing to receive it, suggesting that vaccines are seen as positive 
interventions in MSM [17]. Although HIV vaccination was not included in this review, as it 
is not yet available, the meta-analysis identified the same predictors as the present review 
across all vaccines, in particular risk perceptions, attitudes towards the vaccine and perceived 
barriers. Consequently, MSM experience additional challenges in accessing and utilising 
specialist healthcare services which compromises vaccine acceptability, uptake and 
completion when compared with universal vaccination programmes. Hence, in the absence of 
gender-neutral vaccination programmes, strategies that target MSM should adopt an 
integrated approach that would serve their unique healthcare needs.[114] Such an approach 
must deliver culturally sensitive healthcare programmes recognising physical, social and 
mental health issues faced by sexual and gender minorities that contribute to health 
inequalities. Access to vaccination services should be extended beyond typical healthcare 
settings with adequate support from the community and public policies. As such, countries 
that cannot provide specialist MSM-inclusive services should consider universal vaccination, 
as they may not achieve optimal vaccine coverage for the selective programme in line with 
cost-effectiveness modelling.
Theoretical framework
To guide the development of vaccination programmes for MSM, we developed a 
social-ecological framework that situates vaccine-related behaviours within an interrelated 
system (Figure 3). The framework conceptualises vaccination behaviours through motivation 
for vaccines, their initiation and completion, and proposes six levels of factors facilitating 
vaccine acceptability and behaviours needed for optimal rates to be achieved. The framework 
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also outlines specific obstacles within the context of public and community health as well as 
healthcare services. It acknowledges environmental factors associated with vaccination 
behaviour, such as the role of referent groups as well as location, international policies and 
vaccination guidelines.  
Barriers and facilitators are influenced by specific structural and socio-cultural 
contexts, which differ between countries and the structure of their healthcare services. Each 
may need to develop a unique strategy for targeting MSM concerning age, settings in which 
the vaccine is available or whether it is given for free, or paid by the patient or their insurer. 
For example, considering the differences in health services between the US and the UK, 
which would influence the provision and delivery of vaccination programmes having an 
impact on the experience of barriers and facilitation for uptake and completion. MSM in the 
UK may refuse vaccination for different reasons to MSM in the US. Thus, our framework 
considers that the socio-cultural context should determine appropriate and effective vaccine 
promotion interventions.
Strengths and limitations
Our systematic review provides a comprehensive summary of research on vaccination 
acceptability and behaviour in MSM across all available vaccines against STIs. Our 
theoretical framework identifies constructs relevant for MSM-selective vaccination strategy, 
which were also recognised in similar socio-ecological models.[115-116] The results of the 
meta-analysis need to be treated with caution, especially when considering potential 
moderators due to the heterogeneity of measures used. Previous reviews have highlighted the 
need to standardise vaccine acceptability and uptake measures, proposing a validated scale 
and harmonising monitoring and evaluation outcomes.[10] The present review synthesised 
literature about vaccine uptake and completion looking at convenience samples of MSM, 
mostly accessing healthcare settings, over-representing populations with easier access to 
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vaccination services. There is a possibility that the pooled rates may be overestimated, as 
MSM recruited from non-clinical settings showed lower acceptability and uptake. The 
findings may be skewed towards MSM residing in high-income countries and urbanised 
areas, who are comfortable participating in LGBT-communities; the views of those on the 
community margins, such MSM who do not identify as ‘gay’, ‘bisexual’, or of ethnic 
minority, may be underrepresented.[80] No qualitative studies were included in this review, 
hence the understanding of contexts in which the vaccination behaviours occurred is limited 
and warrant further research. 
This review comprehensively collates factors associated with vaccination behaviours 
across multiple vaccines recommended for MSM and a specific overlap of correlates across 
studies was found. However, there might be other unexplored factors that could be associated 
with vaccination behaviours in MSM such as marital status, personality traits, internalised 
homophobia, participation in LGBT activism, sexual health anxiety, depression and medical 
mistrust. One systematic review identified the role of parental attitudes towards vaccination 
for their children, but little is known about parental uptake in the context of MSM 
vaccination.[117] These factors should be explored in future studies on vaccination 
behaviours in MSM. Previous systematic reviews identified interventions to increase 
vaccination [118-119] but data specific to MSM were not synthesised.  Most studies in our 
review were cross-sectional in design with only a few examining specific interventions such 
as awareness campaigns, a reminder system or a mobile phone application. Future research 
need to identify the most effective intervention to increase vaccination uptake and completion 
in MSM. 
Conclusion
This review indicates that vaccination rates in MSM are sub-optimal when compared 
with the assumptions of cost-effectiveness modelling. While selective vaccination 
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approaches, in the absence of universal strategies, could directly protect those utilising 
specialist healthcare services, MSM with limited access to vaccines remain unprotected. 
Cost-effectiveness modelling of vaccinations for MSM need to adjust their parameters to 
reflect barriers to vaccine motivation, initiation and completion evidenced from the literature. 
When developing effective vaccination programmes for MSM policy-makers and public 
health intervention developers need to consider multi-level factors that influence vaccination 
behaviours. Our proposed theoretical framework can inform policies, guidelines and 
educational training of HCPs to maximise clinical and cost-effectiveness of MSM-selective 
vaccination programmes. Future research needs to explore the effectiveness of interventions 
aimed at increasing vaccination rates in MSM and other sexual and gender minority groups at 
risk of STIs. 
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